New Focus Alert (NASDAQ: MIRA) Has 317%+ Upside According to Research Report

New NASDAQ Breakout Alert For 11/20 Trading Session MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) Brand New Analyst Report Pegs a $16.50 Price Target ["Representing 371% Upside Gain From Current Price"]( Developing The Next Generation FDA Approved Novel Synthetic T∙H∙C Analog Hi “FDR” Member, This is Michael Reece with “FinancialDrivenResearch” delvering you your new breakout alert for Monday trading session 11/20 MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA). MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) current price is $3.50/share. Zacks Small-Cap Research just released a game-changing research report predicting a 12- month price target at a staggering $16.50/share! (MIRA) Has a Potential 371% Upside From Current Price >> [See The Full Report Here Now]( << MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) is a life sciences company focused on the development of MIRA1a, a novel synthetic T∙H∙C analog. MIRA1a is being developed to treat anxiety and cognitive decline in the elderly and neuropathic pain without impurities or the negative side effects associated with c∙a∙n n∙a∙b∙i∙s plant extr∙acts. MIRA1a is classified as an unscheduled dr∙ug by the U.S. Dr∙ug Enforcement Administration (DEA). MIRA Pharmaceuticals is focused on the development and commercialization of new molecular synthetic c∙a∙n∙n∙a∙b∙in∙o∙i∙d analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. MIRA1a is a compound that has shown in preclinical testing indications of having the benefits of T∙H∙C without the negative side effects—potentially aiding Mlns of patients. The company’s earnings report showed good ca∙sh balances. MIRA Pharmaceuticals(NASDAQ: MIRA) Reports Earnings Don't Miss Out on 371% Upside Gain [See The Full Report Here Now]( MIRA reported 3Q earnings of -$0.26 per share as it continues to test and research its potential groundbreaking therapy. Most importantly, the company reported ca∙sh of $5.9 Mln, which is vitally important to a company at this stage and even more so due to the tight credit markets facing smaller companies. In response to these problems with traditional m∙m∙j, MIRA is developing a compound that offers the benefits of c∙a∙n∙n∙a∙b∙is while minimizing the potential negative side effects. That might sound too good to be true, but we are encouraged by the initial test results we’ve seen and impressed by the leadership and their passion for finding a solution to a problem plaguing a vast number of Americans. Overall, technical indicators are signaling a "Bullish STRONG BUY Rating" based on Investing.com technical analysis. MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) Is a First Mover To Market! MIRA1Aa, as it known, is being developed as the first prescription dr∙ug to target the c∙a∙n∙n∙a ∙ b∙i∙n∙o∙i∙d receptors known as CB1 and CB2 for neuropathic pain, anxiety and cognitive enhancements without the impurities of m∙m∙j or its side effects such as those discussed above. Importantly, and for this to be a viable project, the company received great news on November 28, 2022, when the U.S. Dr∙ug Enforcement Agency (DEA) confirmed in writing that it conducted a scientific review of the chemical structure of MIRA1Aa in accordance with the definitions within the Con∙trolled Subs∙tances Act (CSA) and its implementing regulations and determined that MIRA1Aa is not a cont∙rolled sub∙stance or listed chemical. This means that MIRA1Aa can go through the traditional FDA approval process and be used by patients, if approved, without the logistical and financial complications of working with a Schedule 1 dr∙ug —a potential exciting and extremely beneficial breakthrough and a reason, in our view for investors to take a hard look at MIRA before it gets too far along in the process and more inve∙stors push up the price. Four Major Catalyst That Can Produce Triple-Digit Gains For The Future #1. ) MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) received great news on November 28, 2022, when the U.S. Dr∙ug Enforcement Agency (DEA) confirmed in writing that it conducted a scientific review of the chemical structure of MIRA1Aa in accordance with the definitions within the Cont∙rolled Subs∙tances Act (CSA) and its implementing regulations and determined that MIRA1Aa is not a cont∙rolled subs∙tance or listed chemical. #2.) MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) BALTIMORE, Sept. 5, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a novel synthetic T∙H∙C analog, announced its strategic partnership with MZ Group ("MZ"), a renowned international inve∙stor relat∙ions firm. This collaboration aims to enhance MIRA's visibility within the inves∙tment community and spotlight the potential of its d∙r∙u∙g can∙didate, MIRA1a, in treating anxiety, cognitive decline, and neuropathic pain. #3.) MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) Continues to Pursue New Pain Relief. MIRA (NASDAQ:MIRA) reported 3Q earnings of -$0.26 per share as it continues to test and research its potential groundbreaking therapy. Most importantly, the company reported ca∙sh of $5.9 Mln, which is vitally important to a company at this stage and even more so due to the tight credit markets facing smaller companies. MIRA Pharmaceuticals is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic c∙a∙n∙n∙a∙b∙i∙s analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive decline typically associated with early-stage dementia. Most of us have heard about the purported benefits of c∙an∙na∙b∙is (m∙m∙j) in easing pain for sufferers who have had no other valid alternative as well as ease anxiety that people may be experiencing in times of high stress. However, most people also know the potential downside to using that form of “therapy.” First, there’s the minor issue that c∙a∙n∙n∙a∙b∙i∙s remains a Schedule 1 dr∙ug at the Federal level, putting it on par with he∙ro∙ine and L∙S∙D and making it complicated to possess despite the many states having “le∙ga∙liz∙ed” possession and use in various levels and for various uses. #4.) MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than P∙o∙t. BALTIMORE, Sept. 18, 2023 /PRNewswire/ -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of a novel synthetic c∙a∙n n∙a∙b∙i∙s analog named MIRA1a, explored the scientific and social drivers behind its development of MIRA1a today at the Derived D∙r∙u∙g Development Summit. The Company shared data and research that positions MIRA1a as a potential future alternative prescription medication with unique properties not found in as well as the potential for fewer side effects. As an invited speaker at the 6th Annual Derived D∙rug Development Summit held in Boston, Dr. Adam Kaplin, President and Chief Scientific Officer of MIRA Pharmaceuticals, said that Mira1a is a new molecular entity that in pre-clinical studies enhances cognitive performance and diminishes anxiety, while potentially aiding models of neuropathic pain. (MIRA) Has a Potential 371% Upside From Current Price [See The Full Report Here Now]( Conclusion: MIRA-ing the Best of C∙a∙n∙n∙a ∙b∙in∙o∙i∙d∙s MIRA Pharmaceuticals, Inc. (MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of new molecular synthetic c∙a∙n∙n∙a∙b∙i∙n∙o∙i∙d analog for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Their target patient population is also typically experiencing neuropathic pain. MIRA currently trading at the $3.50 range has a incredible upside potential of $16,50 per share. That represents a clean 371% upside potential from here. I am urging all of our members to add MIRA Pharmaceuticals Inc. (MIRA) to the top of your watch list right now, and be ready Monday morning at the opening bell! To Your Trading Success, Michael Reece Editor, Financial Driven Research © 2023 Financial Driven Research, All Rights Reserved. Financial Driven Research (“FDR” or “Company”) is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inves∙tment for any specific individual. FDR full disclosure is to be read and fully understood before using FDR website or joining FDR email or sms list. By viewing FDR website and/or reading FDR email or sms list you are agreeing to FDR full disclosure This publication may contain information regarding inves∙tment ideas and third-party ratings regarding specific securities. We hold n∙o inves∙tment licenses and are thus neither licensed nor qualified to provide inves∙tment adv∙ice. FDR nor its principals are not FINRA-registered broker-dealers or inves∙tment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from FDR to buy or sell any security. Always be extremely careful and consult a licensed inves∙tment professional before making any inves∙tment decision as inves∙ting in securities carries a high degree of risk; you may likely lose some or all of the inves∙tment. This communication is a sponsored advertisement. FDR and/or its subsidiaries and/or affiliates has been compensated $12,000 USD to disseminate this communication. Please note we do not hold positions in stocks we profile. We do not trade in any of our sponsored advertisements, or non-sponsored profiles. We do not accept stock as a form of payment for our sponsored advertisements. Please review the full disc∙laimer at [Disc∙laimer and Disclosure Policy]( for important information regarding this sponsored advertisement. © 2023 FDR. All rights reserved., 1014 W 36th St Unit #83, 21211, Baltimore, United States You may [unsubscribe]( or [change your contact details]( at any time. Powered by:[GetResponse](